Erschienen in:
01.10.2014 | Adis Drug Evaluation
Tiotropium Respimat® Soft Mist™ Inhaler: A Review of Its Use in Chronic Obstructive Pulmonary Disease
verfasst von:
Gillian M. Keating
Erschienen in:
Drugs
|
Ausgabe 15/2014
Einloggen, um Zugang zu erhalten
Abstract
The long-acting anticholinergic agent tiotropium bromide (Spiriva®) is available as a solution for inhalation via Respimat® Soft Mist™ Inhaler in the EU and various other countries for the treatment of chronic obstructive pulmonary disease (COPD). With the Respimat® Soft Mist™ Inhaler there is improved lung deposition of drug (allowing a reduced dosage compared with tiotropium HandiHaler®), the delivered drug dose is independent of inspiratory effort and the prolonged duration of the aerosol cloud should make the co-ordination of actuation and inhalation easier. In patients with COPD, tiotropium Respimat® improved lung function, COPD exacerbations, health-related quality of life and dyspnoea and was at least as effective as tiotropium HandiHaler®. Tiotropium Respimat® was generally well tolerated in patients with COPD, with anticholinergic adverse events among the most commonly reported adverse events. In the TIOSPIR trial, tiotropium Respimat® was noninferior to tiotropium HandiHaler® in terms of all-cause mortality, and the risk of cardiovascular mortality or major adverse cardiovascular events did not significantly differ between the two treatment groups. In conclusion, tiotropium Respimat® Soft Mist™ Inhaler is a useful option for the treatment of patients with COPD.